FI4082334T3 - Muokatun immunoglobuliinin lambda-kevytketjun lokuksen omaavia ei-humaaneja eläimiä - Google Patents

Muokatun immunoglobuliinin lambda-kevytketjun lokuksen omaavia ei-humaaneja eläimiä Download PDF

Info

Publication number
FI4082334T3
FI4082334T3 FIEP22164751.4T FI22164751T FI4082334T3 FI 4082334 T3 FI4082334 T3 FI 4082334T3 FI 22164751 T FI22164751 T FI 22164751T FI 4082334 T3 FI4082334 T3 FI 4082334T3
Authority
FI
Finland
Prior art keywords
human
rodent
gene segments
gene
heavy chain
Prior art date
Application number
FIEP22164751.4T
Other languages
English (en)
Finnish (fi)
Inventor
Chunguang Guo
Faith Harris
Vera Voronina
John Mcwhirter
Natasha Levenkova
Lynn Macdonald
Naxin Tu
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of FI4082334T3 publication Critical patent/FI4082334T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP22164751.4T 2016-11-04 2017-11-03 Muokatun immunoglobuliinin lambda-kevytketjun lokuksen omaavia ei-humaaneja eläimiä FI4082334T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04

Publications (1)

Publication Number Publication Date
FI4082334T3 true FI4082334T3 (fi) 2025-06-10

Family

ID=62025924

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22164751.4T FI4082334T3 (fi) 2016-11-04 2017-11-03 Muokatun immunoglobuliinin lambda-kevytketjun lokuksen omaavia ei-humaaneja eläimiä

Country Status (26)

Country Link
US (2) US10820582B2 (enExample)
EP (4) EP3766343B1 (enExample)
JP (5) JP6884860B2 (enExample)
KR (4) KR102658529B1 (enExample)
CN (2) CN109996441B (enExample)
AU (2) AU2017391167B2 (enExample)
BR (1) BR112019008675A2 (enExample)
CA (1) CA3038720A1 (enExample)
CY (2) CY1123491T1 (enExample)
DK (3) DK4082334T3 (enExample)
ES (3) ES2823305T3 (enExample)
FI (1) FI4082334T3 (enExample)
HR (3) HRP20201403T1 (enExample)
HU (3) HUE052087T2 (enExample)
IL (2) IL308197A (enExample)
LT (3) LT3766343T (enExample)
MA (2) MA53935A (enExample)
MX (2) MX385857B (enExample)
PL (3) PL3766343T3 (enExample)
PT (3) PT4082334T (enExample)
RS (3) RS66884B1 (enExample)
RU (2) RU2021129958A (enExample)
SG (2) SG11201903344XA (enExample)
SI (3) SI3766343T1 (enExample)
SM (3) SMT202200259T1 (enExample)
WO (1) WO2018128691A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
PL2809150T3 (pl) * 2012-02-01 2020-04-30 Regeneron Pharmaceuticals, Inc. Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
JP7752536B2 (ja) * 2019-07-01 2025-10-10 トリアニ・インコーポレイテッド トランスジェニック哺乳動物およびその使用法
AU2021283564B2 (en) * 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
AU2021409906A1 (en) 2020-12-23 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP3028565B1 (en) * 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
SI2480676T1 (sl) 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
DK2813573T1 (da) 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
MX378871B (es) * 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
JP6475172B2 (ja) 2013-02-20 2019-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットの遺伝子組換え
US9788534B2 (en) * 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
WO2015049517A2 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
BR112016028564A2 (pt) 2014-06-06 2018-01-30 Regeneron Pharma método para modificar um locus-alvo em uma célula.
MX384887B (es) 2014-06-23 2025-03-14 Regeneron Pharma Ensamblaje de adn mediado por nucleasa.
CA3176380A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017013104A2 (pt) 2014-12-19 2018-05-15 Regeneron Pharma métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée

Also Published As

Publication number Publication date
MA44091A (fr) 2018-10-24
WO2018128691A1 (en) 2018-07-12
KR20190076024A (ko) 2019-07-01
DK3766343T3 (da) 2022-06-20
PL4082334T3 (pl) 2025-08-11
JP2020501516A (ja) 2020-01-23
EP4567119A3 (en) 2025-09-24
KR20240055863A (ko) 2024-04-29
US12433264B2 (en) 2025-10-07
CN114369157A (zh) 2022-04-19
LT3407709T (lt) 2020-10-12
AU2017391167B2 (en) 2024-02-15
RS66884B1 (sr) 2025-07-31
EP3766343A1 (en) 2021-01-20
IL266282A (en) 2019-06-30
EP3407709B1 (en) 2020-07-29
PL3766343T3 (pl) 2022-09-26
DK4082334T3 (da) 2025-06-02
KR20230020550A (ko) 2023-02-10
EP3407709B9 (en) 2021-10-06
MA53935A (fr) 2021-12-22
SG11201903344XA (en) 2019-05-30
AU2017391167A1 (en) 2019-05-30
HUE071595T2 (hu) 2025-09-28
EP4082334B1 (en) 2025-03-26
PL3407709T3 (pl) 2021-01-11
NZ753456A (en) 2021-08-27
US20180125043A1 (en) 2018-05-10
JP2022130725A (ja) 2022-09-06
EP3766343B1 (en) 2022-05-11
PT4082334T (pt) 2025-05-21
SMT202200259T1 (it) 2022-07-21
RS60886B1 (sr) 2020-11-30
RU2019112589A3 (enExample) 2021-03-30
MX2019005256A (es) 2019-08-05
PT3407709T (pt) 2020-08-20
KR102658529B1 (ko) 2024-04-19
JP7386292B2 (ja) 2023-11-24
LT3766343T (lt) 2022-06-10
SG10201913483XA (en) 2020-03-30
SMT202000558T1 (it) 2020-11-10
RU2757665C2 (ru) 2021-10-20
IL266282B2 (en) 2024-04-01
US20210029978A1 (en) 2021-02-04
LT4082334T (lt) 2025-05-26
CY1123491T1 (el) 2022-03-24
EP4082334A1 (en) 2022-11-02
RU2019112589A (ru) 2020-12-04
RS63390B1 (sr) 2022-08-31
ES2915609T3 (es) 2022-06-23
EP3407709A1 (en) 2018-12-05
CN109996441A (zh) 2019-07-09
CA3038720A1 (en) 2018-07-12
ES2823305T3 (es) 2021-05-06
CN109996441B (zh) 2022-02-08
MX2021010556A (es) 2021-10-01
KR102492433B1 (ko) 2023-01-30
HUE052087T2 (hu) 2021-04-28
AU2024200582A1 (en) 2024-03-28
MX385857B (es) 2025-03-18
SI3766343T1 (sl) 2022-06-30
HRP20201403T1 (hr) 2020-11-27
IL308197A (en) 2024-01-01
JP2025166207A (ja) 2025-11-05
IL266282B1 (en) 2023-12-01
HUE061980T2 (hu) 2023-09-28
JP2023053400A (ja) 2023-04-12
DK3407709T3 (da) 2020-08-31
BR112019008675A2 (pt) 2019-07-09
US10820582B2 (en) 2020-11-03
JP6884860B2 (ja) 2021-06-09
ES3035365T3 (en) 2025-09-02
KR102319069B1 (ko) 2021-11-01
JP2021090455A (ja) 2021-06-17
WO2018128691A8 (en) 2019-02-28
KR20210134059A (ko) 2021-11-08
PT3766343T (pt) 2022-05-30
SMT202500204T1 (it) 2025-07-22
CY1125474T1 (el) 2025-05-09
RU2021129958A (ru) 2021-11-02
SI3407709T1 (sl) 2020-10-30
HRP20250695T1 (hr) 2025-08-01
HRP20220888T1 (hr) 2022-10-28
SI4082334T1 (sl) 2025-06-30
EP4567119A2 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
FI4082334T3 (fi) Muokatun immunoglobuliinin lambda-kevytketjun lokuksen omaavia ei-humaaneja eläimiä
HRP20171357T1 (hr) Ograničeni teški lanac imunoglobulina u miševa
HRP20150262T1 (hr) Miševi sa adam6
SG10201900580RA (en) Non-human animals with modified immunoglobulin heavy chain sequences
HRP20192218T1 (hr) Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
FI3609319T3 (fi) Hiiren malleja ja terapeuttisia molekyylejä
WO2015143414A3 (en) Non-human animals that make single domain binding proteins
MX362904B (es) Anticuerpos con cadena ligera modificada con histidina por ingeniería genética y animales no humanos genéticamente modificados para generarlos.
JP2015502177A5 (enExample)
RU2018119366A (ru) Мыши с гуманизированной легкой цепью
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
ME02817B (me) Generisanje vezujućih molekula
JP2011182801A5 (enExample)
JP2012532598A5 (enExample)
HRP20170322T1 (hr) Miševi koji stvaraju vl vezne proteine
EP4596688A3 (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
MX2021000484A (es) Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph.
HK1250038A1 (zh) 选择结合抗原的轻链可变区的非人动物
AR109451A1 (es) Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
RU2014102617A (ru) Выявление аффинно-зрелых человеческих антител
RU2022109215A (ru) Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
TH169580A (th) หนูเมาส์ที่มีสายเบาแบบทั่วไป
NZ740900B2 (en) Mice that make binding proteins comprising vl domains
RU2019102939A (ru) Собачьи антитела с модифицированными последовательностями ch2-ch3
HK1231692A1 (en) Non-human animals that make single domain binding proteins